Showing results (21-30 of 125) with videos related to

Sort By:
Pageof 13
Cost Effectiveness and Resource Allocation : C/E|February 19, 2025
The cost-effectiveness analysis of newborn screening for inherited metabolic disorders in China using tandem mass spectrometry: a real-world evidenceDunming Xiao, Jiaqi Yuan, Shimeng Liu, et al.
Patient Preference and Adherence|September 7, 2022
Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in ChinaYan Wei, Jin Zhao, Jian Ming, et al.
Advances in Therapy|April 29, 2022
Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in ChinaDunming Xiao, Yue Zhang, Wanxin Chen, et al.
BMC Health Services Research|February 13, 2019
Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug ListWenbin Liu, Lizheng Shi, Monika Sawhney, et al.
Human Resources for Health|May 23, 2022
Tackling brain drain at Chinese CDCs: understanding job preferences of public health doctoral students using a discrete choice experiment surveyShimeng Liu, Yuanyuan Gu, Yi Yang, et al.
International Journal of Environmental Research and Public Health|August 23, 2020
Factors Influencing Medication Non-Adherence among Chinese Older Adults with Diabetes MellitusNingze Xu, Shiyu Xie, Yingyao Chen, et al.
Bioscience Trends|May 16, 2018
Development of health technology assessment in China: New challengesYingyao Chen, Yao He, Xunyouzhi Chi, et al.
Advances in Therapy|February 15, 2024
Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal PerspectiveFuming Li, Yingyao Chen, Dunming Xiao, et al.
International Journal for Equity in Health|May 26, 2019
Overseeing health care facilities in Shanghai, China: regulatory regime, activities and challenges of the governmental regulatory systemYizhong Zhou, Zechang Lu, Zhifeng Yang, et al.
Pharmacoeconomics|March 5, 2015
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetesJinsong Geng, Hao Yu, Yiwei Mao, et al.
Pageof 13